Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)

See the article here:
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

PALO ALTO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that a recent market research study among rheumatologists revealed a high degree of interest in Gloperba® as a liquid colchicine formulation designed for precision dosing.5 Specifically, clinicians using colchicine for prophylaxis of gout flares in adults indicated a strong likelihood to use Gloperba® instead of tablets/capsules in certain at-risk patient populations who have a clinical need for lowered precision dosing to mitigate the risk of colchicine toxicity. Notably, the American College of Rheumatology (ACR) guidelines also reflect this need.6 Scilex is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the dosing recommendations for these patient populations.

See more here:
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid...

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU

See original here:
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over...

CellAssist Software Release 5.0 provides advanced capabilities to accurately count cells and measure their confluence using quantitative phase imaging (QPI) and proprietary algorithms CellAssist Software Release 5.0 provides advanced capabilities to accurately count cells and measure their confluence using quantitative phase imaging (QPI) and proprietary algorithms

Read more:
Thrive Bioscience Debuts Advanced Live Cell Imaging Software, Solving Major Problems in Cell-Based Research and Medicine

COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce a private placement (the “Private Placement”) financing to raise gross proceeds of approximately $5.3 million. The Private Placement includes participation from existing and new shareholders, with the largest new shareholder being MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, accounting for some 25% of the total offering amount. Further, the Private Placement includes significant participation by all members of the Company’s management and the Company’s board of directors.

Read more here:
Evaxion Biotech Announces Private Placement Financing

Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with food allergy. If approved, people taking Xolair would still need to avoid foods they are allergic to (commonly referred to as “food avoidance”). The filing acceptance is based on positive interim analysis results from stage 1 of the National Institutes of Health (NIH)-sponsored pivotal phase III OUtMATCH study evaluating Xolair in patients allergic to peanuts and at least two other common foods. If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure. The FDA is expected to make a decision on approval in the first quarter of 2024.4

Read more:
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase...

DENVER, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Related Sciences (RS), a leading data science-driven drug discovery firm, today announced the appointment of 8 leading biopharma executives as senior advisors to support its growing portfolio of drug programs, data science capabilities, and R&D partnerships:

See the original post:
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca

Oslo, 19 December 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of NOK 117.60 per share. Following this transaction, Carlos de Sousa and closely related parties hold 23,056 shares and 425,535 share options in Ultimovacs ASA.

Read more from the original source:
Ultimovacs ASA: Mandatory notification of trade by primary insider

FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB)

See the article here:
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa

- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce -

Read the original here:
Aclaris Therapeutics Provides Corporate Update

SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities.

View original post here:
LianBio Announces Departure of Chief Executive Officer

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM). This is Galapagos’ third oncology CAR-T program in clinical development.

View original post here:
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.

Read the original post:
Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions

Original post:
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company’s common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company’s common stock now is quoted on the OTC Pink market under the same trading symbol, “FRTX.” The Company has withdrawn its appeal of Nasdaq’s determination to delist the Company’s common stock, which will no longer trade on The Nasdaq Capital Market.

Read more from the original source:
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market

Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth

Read more from the original source:
Bioventus Names Robert Claypoole as President and Chief Executive Officer

Ad Hoc Announcement Pursuant to Art. 53 LR

See original here:
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:

Read the original here:
Burning Rock Announces Results of 2023 Annual General Meeting

Regulated Information – Inside Information

Here is the original post:
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Ad hoc announcement pursuant to Art. 53 LR

Excerpt from:
Basilea announces accelerated loan repayment